• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

作者信息

Chic Nuria, Mayo-de-Las-Casas Clara, Reguart Noemí

机构信息

Medical Oncology, Hospital Clínic, Barcelona, Spain.

Pangaea Oncology, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain.

出版信息

J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014.

DOI:10.1016/j.jtho.2017.02.014
PMID:28532569
Abstract
摘要

相似文献

1
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.奥希替尼获得性耐药后吉非替尼成功治疗晚期非小细胞肺癌
J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014.
2
Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.HM61713治疗失败后，AZD9291成功治疗晚期非小细胞肺癌。
J Thorac Oncol. 2017 Jun;12(6):e72-e74. doi: 10.1016/j.jtho.2017.02.005.
3
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
4
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.表皮生长因子受体（EGFR）Leu792位点的新型突变可能与晚期非小细胞肺癌对奥希替尼的获得性耐药相关。
J Thorac Oncol. 2017 Jun;12(6):e65-e68. doi: 10.1016/j.jtho.2016.12.024. Epub 2017 Jan 16.
5
Osimertinib effective in EGFR T790M-positive lung cancer.奥希替尼对EGFR T790M阳性肺癌有效。
Lancet Oncol. 2017 Jan;18(1):e9. doi: 10.1016/S1470-2045(16)30654-4. Epub 2016 Dec 16.
6
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.奥希替尼与吉非替尼联合治疗 C797S 和 T790M 突变的非小细胞肺癌。
J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006. Epub 2017 Aug 24.
7
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.在 EGFR 突变型 NSCLC 脑转移模型中奥希替尼与其他 EGFR-TKIs 的临床前比较，以及临床脑转移活性的早期证据。
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140. doi: 10.1158/1078-0432.CCR-16-0399. Epub 2016 Jul 19.
8
NICE approves osimertinib for advanced lung cancer.英国国家卫生与临床优化研究所批准奥希替尼用于治疗晚期肺癌。
Lancet Respir Med. 2016 Dec;4(12):954. doi: 10.1016/S2213-2600(16)30368-X. Epub 2016 Nov 1.
9
CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC.奥希替尼在表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌中的中枢神经系统疗效。
Lancet Oncol. 2018 Oct;19(10):e516. doi: 10.1016/S1470-2045(18)30677-6. Epub 2018 Sep 6.
10
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.新型非小细胞肺癌肿瘤疗法在接受新一代酪氨酸激酶抑制剂治疗患者中的心血管安全性
Kardiol Pol. 2018;76(3):670. doi: 10.5603/KP.2018.0061.

引用本文的文献

1
Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review.吉非替尼与贝伐单抗联合用于奥希替尼治疗后出现G719S/S768I突变和获得性C797S（无T790M）的晚期非小细胞肺癌：一例报告及文献复习
Curr Oncol. 2025 Mar 28;32(4):201. doi: 10.3390/curroncol32040201.
2
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC.表皮生长因子受体（EGFR）阳性转移性非小细胞肺癌（NSCLC）患者停用奥希替尼后的治疗模式及资源利用情况
Oncol Ther. 2024 Sep;12(3):549-563. doi: 10.1007/s40487-024-00292-5. Epub 2024 Jul 30.
3
Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach.
寡转移和寡进展性表皮生长因子受体突变的非小细胞肺癌患者的管理：联合治疗方法的现状
Explor Target Antitumor Ther. 2024;5(3):449-464. doi: 10.37349/etat.2024.00228. Epub 2024 May 17.
4
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens.表皮生长因子受体（EGFR）突变的转移性非小细胞肺癌患者接受EGFR酪氨酸激酶抑制剂和铂类化疗方案治疗后的治疗模式及不良事件相关住院情况
Drugs Real World Outcomes. 2023 Dec;10(4):531-544. doi: 10.1007/s40801-023-00383-1. Epub 2023 Sep 2.
5
Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present).基于喹唑啉衍生物作为表皮生长因子受体激酶抑制剂的构效关系研究（2017年至今）
Pharmaceuticals (Basel). 2023 Apr 3;16(4):534. doi: 10.3390/ph16040534.
6
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.迈向新一代 EGFR 抑制剂：非小细胞肺癌中 EGFR 突变介导的奥希替尼耐药概述。
Cell Commun Signal. 2023 Apr 11;21(1):71. doi: 10.1186/s12964-023-01082-8.
7
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With -Mutant NSCLC: A Case Report.在一名携带EGFR突变的非小细胞肺癌患者中使用吉非替尼通过T790M缺失和C797S获得克服对奥希替尼的耐药性：一例报告
JTO Clin Res Rep. 2022 Dec 28;4(2):100456. doi: 10.1016/j.jtocrr.2022.100456. eCollection 2023 Feb.
8
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择
Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.
9
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
10
exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review.外显子19缺失转换及p.L792Q突变的发生作为奥希替尼新的耐药机制：一例报告及文献综述
Transl Cancer Res. 2019 Jan;8(Suppl 1):S64-S69. doi: 10.21037/tcr.2018.09.13.